2021
DOI: 10.3389/fpubh.2021.712027
|View full text |Cite
|
Sign up to set email alerts
|

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis

Abstract: Background: Chronic Kidney Disease (CKD) is a global chronic disease with increasing prevalence in recent years, particularly CKD accompanied by Secondary Hyperparathyroidism (SHPT) leads to reduced quality of life, increased mortality, a considerable economic burden for patients and society. The aim of this study was to investigate the cost-effectiveness analysis of paricalcitol vs. calcitriol + cinacalcet for CKD patients with SHPT in China in 2020.Methods: A Markov model was conducted employing data derived… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 59 publications
0
2
0
Order By: Relevance
“…The physiological response to these abnormalities includes increased serum parathyroid hormone (PTH) and parathyroid hyperplasia. It is associated with cardiovascular disease and fracture risk factors, resulting in lower quality of life and higher mortality [ 2 , 3 ]. Secondary hyperparathyroidism occurs in about 70% of patients with advanced CKD and about 55% of hemodialyzed patients [ 4 , 5 ].…”
Section: Introductionmentioning
confidence: 99%
“…The physiological response to these abnormalities includes increased serum parathyroid hormone (PTH) and parathyroid hyperplasia. It is associated with cardiovascular disease and fracture risk factors, resulting in lower quality of life and higher mortality [ 2 , 3 ]. Secondary hyperparathyroidism occurs in about 70% of patients with advanced CKD and about 55% of hemodialyzed patients [ 4 , 5 ].…”
Section: Introductionmentioning
confidence: 99%
“…Secondary hyperparathyroidism (SHPT) has a high prevalence in patients on maintenance hemodialysis. The prevalence of SHPT in maintenance HD patients is approximately 55–68.6% [ 1 , 2 ]. The high level of parathyroid hormone (PTH) in SHPT patients is closely associated with mineral and bone disorders and mortality [ 3 5 ].…”
Section: Introductionmentioning
confidence: 99%